Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs bevacizumab + triamcinolone for retinal vascular occlusions
IRCT20130812014333N185Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of bevacizumab and triamcinolone acetonide in Ocular Vascular Occlusion (OVO) (2 arms), sponsored by Kermanshah University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
bevacizumabtriamcinolone acetonide
03
Conditions
Ocular Vascular Occlusion (OVO)
Beyond the preview
Go deeper on IRCT20130812014333N185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N185.